Nivolumab,Ipilimumab
BMS
['niche,(-niche 2),(-niche-2),(-niche2)', 'congrat']
in 6 years time from participant at the #mccr course where the basis of the niche study was laid to presenter at a presidential session #esmo22 how nice to see 2016 s mentor bob maki congratulating myriam with this success.
Head of Med Oncology @NKI_nl Amsterdam. Sarcoma; AYA cancer. Prof @ErasmusMC President of @EORTC and chair @AYAzorgnetwerk @COMPRAYA_study